日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities

一项针对合并其他疾病的慢性淋巴细胞白血病患者的苯达莫司汀和利妥昔单抗的I期剂量探索研究

Danilov, Alexey V; Lewis, Lionel D; Lansigan, Frederick; Roudaia, Liya; Findley, Darcie L; Jones, Susan Y; Highhouse, Brian; Beaulieu, Bernard B; Brown, Jennifer R

CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

CBFβ 对 AML1-ETO 和 TEL-AML1 活性至关重要

Roudaia Liya, Cheney Matthew D, Manuylova Ekaterina, Chen Wei, Morrow Michelle, Park Sangho, Lee Chung-Tsai, Kaur Prabhjot, Williams Owen, Bushweller John H, Speck Nancy A

Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.

MYND 结构域识别 SMRT/N-CoR 的结构基础及其对 AML1/ETO 活性的贡献

Liu Yizhou, Chen Wei, Gaudet Justin, Cheney Matthew D, Roudaia Liya, Cierpicki Tomasz, Klet Rachel C, Hartman Kari, Laue Thomas M, Speck Nancy A, Bushweller John H

Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles.

RUNX1 和 RUNX2 中的致病突变会产生无功能、显性负性或功能减弱的等位基因

Matheny Christina J, Speck Maren E, Cushing Patrick R, Zhou Yunpeng, Corpora Takeshi, Regan Michael, Newman Miki, Roudaia Liya, Speck Caroline L, Gu Ting-Lei, Griffey Stephen M, Bushweller John H, Speck Nancy A